

1 **A SIMPLE COLORIMETRIC MOLECULAR DETECTION OF NOVEL**
2 **CORONAVIRUS (COVID-19), AN ESSENTIAL DIAGNOSTIC TOOL FOR**
3 **PANDEMIC SCREENING**

4 Pazhanimuthu Annamalai, Madhu Kanta, Pazhanivel Ramu, Baskar Ravi,
5 Kokilavani Veerapandian and Rengarajan Srinivasan*

6 Aura Biotechnologies Private Limited, Survey No. 270/1, Plot No. 1 & 2, Galaxy
7 Road, Ayanambakkam, Chennai – 600 095, Tamil Nadu, India.

8

9 *Corresponding Author

10 Dr Rengarajan Srinivasan, Chief Scientific Officer, Aura Biotechnologies Private
11 Limited, Survey No. 270/1, Plot No. 1 & 2, Galaxy Road, Ayanambakkam,
12 Chennai – 600 095, Tamil Nadu, INDIA.

13 E-mail: rengarajan.s@aurabiotech.com, Phone: +91 (0) 79042 51771

14

15 Short Title: SARS-CoV-2 Detection by LAMP and RT-LAMP

16

17 Key Words: SARS-CoV-2 infection; rapid diagnosis; LAMP assay; point of care
18 detection

19

20

21

22

23 **Abstract**

24 The recent outbreak of the newly emerged novel coronavirus (SARS-CoV-2)
25 presents a big challenge for public health laboratories as virus isolates are not
26 available while there is an increasing evidence that the epidemic is more
27 widespread than initially thought, as well as spreading internationally across
28 borders through travellers does already happen warranting a methodology for the
29 rapid detection of the infection to control SARS-CoV-2. Aim: We intended to
30 develop and deploy a robust and rapid diagnostic methodology using LAMP
31 assay for use in point of care settings to detect SARS-COV-2 infection.
32 Methodology: In the present study, we have developed a validated rapid
33 diagnostic procedure to detect SARS-CoV-2 using LAMP assay, its design
34 relying on isothermal amplification of the nucleic acids of the SARS-CoV-2.
35 Results: The LAMP assay developed detects SARS-CoV-2 infection rapidly
36 with high sensitivity and reliability. The data generated by LAMP assay were
37 comparable and at par with the data generated by real-time PCR method.
38 Conclusion: The present study demonstrates that the LAMP assay developed
39 was a rapid, reliable, sensitive and cost effective method to detect SARS-CoV-2
40 infection in a point of care as well as in laboratory settings.

41

42

43

44 **Introduction**

45 Novel coronavirus (SARS-CoV-2) infection is thought to have spread to human
46 populations from the animal kingdom in November or December, 2019, as
47 implied by the phylogeny of genomic sequences obtained from early cases.¹ The
48 genetic epidemiology implies that from the commencement of December, 2019,
49 when the first cases were retrospectively found out in Wuhan, the increase
50 in infection has been almost entirely driven by human-to-human
51 transmission and not as the result of persistent spillover. There was a colossal
52 transmission of the virus within a matter of weeks in Wuhan, and people in the
53 resulting links of transmission spread infection by national and international travel
54 during the holidays of Chinese new year.

55 SARS-CoV-2 appears to have different epidemiological characteristics when
56 compared to SARS-CoV-1. SARS-CoV-2 replicates efficiently in the upper
57 respiratory tract and seems to cause less abrupt onset of symptoms, comparable
58 to the conventional human coronaviruses that are a major reason of common
59 colds in the winter season.² Infected individuals, during the prodrome period,
60 produce a large quantity of virus in the upper respiratory tract, are mobile, and
61 carried on routine day-to-day activities, contributing to the spread of infection.

62 SARS-CoV-2 also has affinity for cells in the lower respiratory tract and can
63 replicate there also, causing radiological evidence of lesion in the lower
64 respiratory tract in patients who do not exhibit clinical pneumonia.¹ There appear
65 to be three key patterns of the clinical route of infection: mild illness with upper

66 respiratory tract presenting symptoms; non-life-threatening pneumonia; and
67 severe pneumonia with acute respiratory distress syndrome (ARDS) that begins
68 with mild symptoms for 7 – 8 days and then advances to rapid deterioration
69 requiring advanced life support.³ At present, SARS-CoV-2 appears to spread
70 from person to person by the same mechanism as other common cold or
71 influenza viruses *i.e.*, face to face contact with a sneeze or cough or due to
72 contact with secretions of people who are infected. The role of faecal – oral
73 transmission is yet to be established in SARS-CoV-2 but was found to occur
74 during the SARS outbreak.⁴

75 A possible scenario based on the existing evidence now is that the newly
76 identified SARS-CoV-2, similar to the seasonal influenza virus, is causing mild
77 and self-limiting disease in majority of people who are infected, with severe
78 disease more possibly among aged people or those with comorbidities, such as
79 diabetes, pulmonary disease, and other chronic conditions.

80 Viruses of the family Coronaviridae have a single-strand, positive-sense RNA
81 genome of 26 – 32 kilo bases in length.⁵ Coronaviruses have been reported in a
82 number of avian hosts,^{6, 7} as well as in a variety of mammals, including camels,
83 bats, mice, dogs, and cats. Novel mammalian coronaviruses are now regularly
84 been identified.⁵ For instance, an HKU2-related coronavirus of bat origin was
85 identified to be responsible for a fatal acute diarrhea syndrome in pigs in the year
86 2018.⁸ Amongst several corona viruses that are pathogenic to humans, most are
87 associated with mild clinical symptoms,⁵ with two notable exceptions: severe

88 acute respiratory syndrome (SARS) coronavirus (SARS-CoV), a novel beta-
89 coronavirus that emerged in Guangdong, southern China, in November, 2002⁹
90 and resulted in more than 8000 human infections and 774 deaths in 37 countries
91 during 2002 – 2003;¹⁰ and Middle East respiratory syndrome (MERS)
92 coronavirus (MERS-CoV), which was first detected in Saudi Arabia in 2012¹¹ and
93 was accountable for 2494 laboratory-confirmed cases of infection and 858
94 casualties since September, 2012, including 38 deaths following a single
95 introduction into South Korea.^{12, 13} In late December, 2019, several patients
96 with viral pneumonia were found to be epidemiologically associated with the
97 Huanan seafood market in Wuhan, in the Hubei province of China, where a
98 number of non-aquatic animals such as birds and rabbits were also on sale
99 before the outbreak. A novel, human-infecting coronavirus,^{14, 15} temporarily
100 named 2019 novel coronavirus (2019-nCoV), was identified with use of
101 next-generation sequencing. As of Jan 28, 2020, China has reported more than
102 5900 confirmed cases as well as more than 9000 suspected cases of 2019-nCoV
103 infection across 33 Chinese provinces or municipalities, with 106 casualties.
104 Furthermore, 2019-nCoV has now also been reported in Thailand, Japan, South
105 Korea, Malaysia, Singapore, and the USA. People in the health care industry are
106 at high risk of infection, and health-care-associated intensification of transmission
107 is of great concern as is always the case for emerging infections. Most of the
108 infected patients had a high fever and some had dyspnoea, with chest
109 radiographs revealing invasive lesions in both lungs.^{1, 16} Non-pharmaceutical

110 interventions remain vital for the management of SARS-CoV-2 infection as there
111 is no licensed vaccine or coronavirus antiviral available.

112 At present, for the qualitative detection of the SARS-CoV-2 in nasopharyngeal
113 swabs, alveolar lavage fluid, sputum, and blood samples, reverse transcription-
114 PCR (RT-PCR) kits are being rapidly developed.¹⁷ Nevertheless, RT-PCR tests
115 require skilled personnel and well-equipped laboratories that restrict this
116 detection method at point-of-care centres and smaller clinics. The increasing
117 number of suspected cases surpasses the capacity of many hospitals, leaving
118 many patients untested thereby challenging the control of spread of the disease.

119 A rapid, point-of-care molecular diagnostics for the SARS-CoV-2 detection is the
120 urgent need of the hour to address the crisis. Therefore, in the present study we
121 have developed a simple closed-tube molecular diagnostic test for SARS-CoV-2
122 that can be carried out at point-of-care centres and small clinics by minimally
123 trained personnel without the need for sophisticated equipments. In the present
124 study, we report the development of a rapid and reliable molecular detection
125 method to identify the newly emerged coronavirus SARS-CoV-2 by loop-
126 mediated isothermal amplification assay.

127

128

129

130

131

132 **Methods**

133 Procurement of RNA Clones of Genes of Interest

134 The RNA Clones of genes of interest, *N* gene, *ORF* gene and the internal control
135 gene, RNase P were procured as clones from GenScript, USA. The sequences
136 of RNA clones of the genes of interest are as follows:

137 N Gene:

138 caccgcgaatcctgctaacaatgctgcaatcgtgctacaactcctcaaggaacaacattgccaaaaggcttcta
139 cgcagaagggagcagagggcggcagtcagcctcttctcgttctcatcacgtagtcgcaacagttcaagaaatt
140 caactccaggcagcagtaggggaacttctcctgctagaatggctggcaatggcgggatgctgctcttgctttgct
141 gctgcttgacagattgaaccagcttgagagcaaaatgtctggttaaaggccaacaacaaggccaaactgt
142 cactaagaaatctgctgctgaggcttctaagaagcctcggcaaaaacgtactgccactaaagcatacaatgtaa
143 cacaagct

144 ORF Gene

145 atcgtgttgctgtactgccgttgccacatagatcatccaaatcctaaaggatttttgactaaaaggtaagtatgta
146 caaatacctacaacttgctaatgaccctgtgggtttacacttaaaaacacagctctgtaccgtctgcggtatgtgg
147 aaaggttatggctgtagttgtgatcaactccgcaacctatgcttcagtcagctgatgcacaatcgtttttaacgg
148 gtttgcggtgtaagtgcagcccgtcttacaccgtgcggcacaggcactagtagtgcgtatacagggctttga
149 catctacaatgataaagtagctggtttgctaaattcctaaaaactaattggttgcgcttccaagaaaaggacgaag
150 atgacaatttaattgattcttactttgtagttaagagacacactttcttaactaccaacatgaagaaacaattataat
151 ttacttaaggattgtccagctgttgctaaacat

152

153

154 RNaseP Gene

155 atggcgggtggttgacagattggacctgcgagcgggtctgacctgaaggctctgcgcgactgtggagacagcc
156 gctcacctggctattcagttgtgctatcaatcatatcggtgactttaaggaaaagaaacaggaattgaaaaacc
157 agtagctgtttctgaactcttcacaacttgccaattgtacagggaaaatcaagaccaattaaatttaactagatt
158 aacaattattgtctcggatccatctcactgcaatgtttgagagcaacttctcaagggcccggctctatgatgtgttg
159 cagttttccaaagacagaaaagcttttcatattgcttgcacacattagatgtggatttagctgcataactgtaaca
160 gagaaactaccattttacttcaaagacctcctattaatgtggcgattgaccgaggcctggctttgaaactgtctat
161 agccctgctatcaaagactccacaatgagaaggatatacaattccagtgccctcaatttgatgcaaactgcaaa
162 ggaaagaatgtaattatactagtgtgcagaaaggccttagaaataagagggccatgacgtggcaaatct
163 aggctgtgtttgggctctctgaaagtgacgccaaggctgcggtgtccaccaactgccgagcagcgcttctccat
164 ggagaaactagaaaaactgcttttgaattatctctacagtgaagaaacctcggccatcagaaggagatgaag
165 attgtctccagctccaagaaagccaagtgtgagggctga

166

167 LAMP Primers

168 The LAMP primers (Table 1) targeting genes of interest, N and ORF genes and
169 the internal control RNaseP gene were designed using Primer Explorer ver. 5
170 (<http://primerexplorer.jp/lampv5e/index.html>). These primers were synthesized by
171 Eurofins Scientific India Pvt. Ltd, Bangalore, India). The primers used for the
172 amplification of the genes of interest and the internal control gene are given in
173 Table 1.

174

175

176 Colorimetric LAMP Reaction

177 The LAMP reaction was performed in a total of 25 μ l reaction volume using para-
178 cresol dye-based AURA 2 X LAMP master mix (15 μ l) that contained each of the
179 four dNTPs (1.4 mM), thermo stable reverse transcriptase (1 μ l), AURA *Bst*
180 polymerase (8 U), the primers (1.6 μ M FIP and BIP; 0.4 μ M LB and LF; 0.2 μ M
181 F3 and B3) and 120 μ M para-cresol dye. The target RNA at different copy
182 numbers (10^{-6} to 10^0) was added to the master mix and the final reaction volume
183 was made up to 25 μ l with water. NTC had all the reaction components except
184 the target RNA. The reaction was carried out at 65°C for 30 minutes.

185

186 Real-Time LAMP Reaction

187 The real-time LAMP reaction was performed in a total of 25 μ l reaction volume
188 using para-cresol dye-based AURA 2 X LAMP master mix (15 μ l) that contained
189 each of the four dNTPs (1.4 mM), thermo stable reverse transcriptase (1 μ l),
190 AURA *Bst* polymerase (8 U), the primers (1.6 μ M FIP and BIP; 0.4 μ M LB and
191 LF; 0.2 μ M F3 and B3) and 120 μ M para-cresol dye as well as 1 X Evagreen and
192 1X ROX reference dyes. The target RNA at different copy numbers (10^{-6} – 10^0)
193 was added to the master mix and the final reaction volume was made up to 25 μ l
194 with water. NTC had all the reaction components except the target RNA. The
195 fluorescent signals were observed automatically by MxPro 3000P Real-Time
196 PCR System (Agilent Technologies, New York, USA). The C_t values obtained for

197 different copy numbers ($10^{-6} - 10^0$) of the N and ORF target RNAs as well as for
198 internal control RNaseP RNA were given in Table 2.

199

200 **Role of the Funding Source**

201 The present study was not supported by funding agency / organization.

202

203 **Results and Discussion**

204 *Real-Time LAMP Detection of SARS-CoV-2*

205 The S-type amplification curves demonstrated a positive result, while the smooth
206 straight line represents the NTC. From the amplification curves, it is evident that
207 the set of primers used for the specific detection of the
208 *N* gene, *ORF* gene and the internal control RNaseP gene in the present study
209 demonstrated increased fluorescence signals in the presence of the templates of
210 the respective genes only and no fluorescence signals was observed for NTC
211 (Fig. 1A, 1B, 1C). The sensitivity was found to be high the viral RNA is detected
212 even up to 10 copy number with good specificity.

213 The present study was aimed at developing a LAMP assay specifically for the
214 detection of *N* and *ORF* genes of SARS-CoV-2 (COVID-19) and hence LAMP
215 primers were designed for the amplification of these two genes along with the
216 internal control RNaseP gene using the Primer Explorer (ver. 5) software. The
217 designed primers were validated by performing a real-time LAMP assay with the
218 clones of the *N* and *ORF* gene as well the internal control RNaseP gene and

219 from the amplifications curves generated in the assay, it is observed that the
220 amplicons generated were respective to each of N, ORF and RNaseP genes
221 from the LAMP reaction mix that contained the respective target DNAs and
222 nothing got amplified from the NTC reaction mix thereby demonstrating that the
223 designed primers are the valid ones to use for the detection of SARS-CoV-2
224 infection in suspected / affected individuals.

225 *Colorimetric LAMP Detection of SARS-CoV-2*

226 The gradual change in the colour from pink (NTC) to yellow (target DNAs 10^0)
227 was visually evident as a result of no binding of the target genes' (N and ORF
228 genes as well as the internal control gene RNaseP) specific primers in NTC
229 LAMP reaction mix to the gradual increased binding of specific primers to the
230 target genes (N and ORF genes as well as the internal control gene RNaseP) of
231 interest in 10-fold serial dilution ($10^0 - 10^{-6}$) of LAMP reaction mixes (Fig. 2A, 2B,
232 2C).

233 In the current study, at the end of the LAMP assay, we observed a dilution-
234 dependent colour difference (*i.e.*, pink to yellow) in the reactions mixes that
235 contained low to high copy numbers of the target DNAs *N* and *ORF* of SARS-
236 CoV-2 as well as the internal control RNaseP gene, thus suggesting that the
237 target DNAs specific primers designed got bound to the specific target DNAs and
238 amplified the same to several magnitude.

239

240 **Conclusion**

241 To conclude, the present study has demonstrated that SARS-CoV-2 infection in
242 humans can be detected by LAMP and RT-LAMP assays by targeting the *N* and
243 *ORF* genes of SARS-CoV-2 with high sensitivity and specificity. In addition, our
244 study has also confirmed that LAMP assay is a potential, suitable, cost effective
245 and time saving specific method for the rapid diagnosis of SARS-CoV-2 infection
246 and also aids to a great extent in the screening of this pandemic infection,
247 surveillance as well as combating the spread of SARS-CoV-2 infection at the
248 point of risk.

249

250

251 **References**

- 252 1. GISAID: Genomic epidemiology of BetaCoV 2019–2020.
253 <https://www.gisaid.org/epiflu-applications/next-betacov-app/> (accessed Feb
254 11, 2020).
- 255 2. Chan JF-W, Yuan S, Kok, K-H, et al. A familial cluster of pneumonia
256 associated with the 2019 novel coronavirus indicating person-to-person
257 transmission: a study of a family cluster. *Lancet* 2020; published online
258 Jan 24. [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9).
- 259 3. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory
260 syndrome. *N Engl J Med* 2003; 349: 2431–41.
- 261 4. European Centre for Disease Prevention and Control. Severe acute
262 respiratory syndrome—Annual Epidemiological Report 2016 (2014 data).
263 Dec 30, 2016. [https://www.ecdc.europa.eu/en/publications-data/severe-](https://www.ecdc.europa.eu/en/publications-data/severe-acute-respiratory-syndrome-annual-epidemiological-report-2016-2014-data)
264 [acute-respiratory-syndrome-annual-epidemiological-report-2016-2014-data](https://www.ecdc.europa.eu/en/publications-data/severe-acute-respiratory-syndrome-annual-epidemiological-report-2016-2014-data)
265 (accessed Feb 12, 2020).
- 266 5. Lee SH. The SARS epidemic in Hong Kong. *J Epidemiol Community*
267 *Health* 2003; 57: 652–54.
- 268 6. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and
269 pathogenesis of coronaviruses. *Trends Microbiol* 2016; 24: 490–502.
- 270 7. Cavanagh D. Coronavirus avian infectious bronchitis virus. *Vet Res* 2007;
271 38: 281–97.

- 272 8. Ismail MM, Tang AY, Saif YM. Pathogenicity of turkey coronavirus in
273 turkeys and chickens. *Avian Dis* 2003; 47: 515–22.
- 274 9. Zhou P, Fan H, Lan T, et al. Fatal swine acute diarrhoea syndrome caused
275 by an HKU2-related coronavirus of bat origin. *Nature* 2018; 556: 255–58.
- 276 10. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat*
277 *Med* 2004; 10 (suppl 12): S88–97.
- 278 11. Chan-Yeung M, Xu RH. SARS: epidemiology. *Respirology* 2003; 8 (suppl):
279 S9–14.
- 280 12. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA.
281 Isolation of a novel coronavirus from a man with pneumonia in Saudi
282 Arabia. *N Engl J Med* 2012; 367: 1814–20.
- 283 13. Lee J, Chowell G, Jung E. A dynamic compartmental model for the Middle
284 East respiratory syndrome outbreak in the Republic of Korea: a
285 retrospective analysis on control interventions and superspreading events.
286 *J Theor Biol* 2016; 408: 118–26.
- 287 14. Lee JY, Kim YJ, Chung EH, et al. The clinical and virological features of
288 the first imported case causing MERS-CoV outbreak in South Korea, 2015.
289 *BMC Infect Dis* 2017; 17: 498.
- 290 15. Tan W, Zhao X, Ma X, et al. A novel coronavirus genome identified in a
291 cluster of pneumonia cases—Wuhan, China 2019-2020. *China CDC*
292 *Weekly* 2020; 2: 61–62.

293 16. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
294 pneumonia in China, 2019. N Engl J Med 2020; published online Jan 24.
295 DOI:10.1056/NEJMoa2001017.

296

297 **Declaration of Interests**

298 All the authors of this manuscript declare that there is no conflict of interest.

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315 **Table 1: Primers used for LAMP and RT-LAMP**

Gene of Interest	Sequence
<i>N gene</i>	F3-GCCAAAAGGCTTCTACGCA B3-TTGCTCTCAAGCTGGTTCAA FIP-TCCCCTACTGCTGCCTGGAG-CGGCAGTCAAGCCTCTTC BIP-TTCTCCTGCTAGAATGGCTGGC-TCTGTCAAGCAGCAGCAAAG LF-CGACTACGTGATGAGGAACGA LB-AATGGCGGTGATGCTGCTCTT
<i>ORF gene</i>	F3-TGCTTCAGTCAGCTGATG B3-TTAAATTGTCATCTTCGTCCTT FIP-TCAGTACTAGTGCCTGTGCCACAATCGTTTTTAAACGGGT BIP-TCGTATACAGGGCTTTTGACATCTATCTTGGAAGCGACAACAA LF-CTGCACTTACACCGCAA LB-GTAGCTGGTTTTGCTAAATTCC
<i>RNaseP</i>	F3-GTTTCTGAACTCTTCACA ACTT B3-TCTAAATGTGTGCAAGCAATA FIP-AGATGGATCCGAGACAATAATTGTTAATTGTACAGGGAAAATCAAGA BIP-TGCAATGTTTTGAGAGCAACTTCGAAAAAGCTTTTCTGTCTTTGG LB-GGGCCCGGCTCTATGAT

316


317

318

319 **Table 2: Cycle Threshold Values**

S. No.	Name of the Target RNA	Copy Number of Target RNA	Cycle Threshold (C_t) Value
1	<i>N</i>	10^7	14.13
		10^6	15.42
		10^5	18.20
		10^4	20.16
		10^3	24.56
		10^2	28.61
		10^1	34.36
2	<i>ORF</i>	10^7	14.02
		10^6	15.62
		10^5	17.38
		10^4	18.69
		10^3	21.99
		10^2	28.22
		10^1	33.41
3	RNaseP	10^7	21.26
		10^6	23.80
		10^5	25.13
		10^4	26.88
		10^3	30.07
		10^2	32.62
		10^1	No CT

321 **Figure 1**




322

323

A. N Gene

324

325




326

327

B. ORF Gene

328



329


330

C. RNaseP Gene

331

332

Figure 2



333

334 1: 10^7 copies of *N* gene; 2: 10^6 copies of *N* gene; 3: 10^5 copies of *N* gene;

335 4: 10^4 copies of *N* gene; 5. 10^3 copies of *N* gene; 6: 10^2 copies of *N* gene;


336 7: 10^1 copies of *N* gene; 8: No Template Control

337

A. *N* Gene

338

339




340
341 1: 10^7 copies of *ORF* gene; 2: 10^6 copies of *ORF* gene; 3: 10^5 copies of *ORF* gene;
342 4: 10^4 copies of *ORF* gene; 5. 10^3 copies of *ORF* gene; 6: 10^2 copies of *ORF* gene;
343 7: 10^1 copies of *ORF* gene; 8: No Template Control

344 **B. *ORF* Gene**

345

346

347



348
349 1: 10^7 copies of RP gene; 2: 10^6 copies RP gene; 3: 10^5 copies of RP gene;
350 4: 10^4 copies of RP gene; 5. 10^3 copies of RP gene; 6: 10^2 copies of RP gene;
351 7: 10^1 copies of RP gene; 8: No Template Control

352 **C. RNaseP (RP) Gene**